Potential Antiangiogenic Treatment Eligibility of Patients With Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Cancer Management and Research - New Zealand
doi 10.2147/cmar.s219984